Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ned Tijdschr Geneeskd ; 161: D1699, 2017.
Artigo em Holandês | MEDLINE | ID: mdl-29171367

RESUMO

A 69-year-old woman with right-sided flank pain, probably based on a ureteropelvic junction obstruction, underwent JJ-catheter placement under fluoroscopic guidance. X-ray showed an appendix filled with shot pellets. This phenomenon has been described earlier in Eskimo hunters, who were known to accidently swallow shot pellets lodged in hunted animals. Shot pellet accumulation can result in appendicitis perforata or lead poisoning.


Assuntos
Apendicite/diagnóstico , Corpos Estranhos , Obstrução Ureteral/diagnóstico , Idoso , Apêndice/patologia , Feminino , Humanos , Metais , Pelve
2.
Minerva Urol Nefrol ; 63(4): 309-15, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21996986

RESUMO

T1 urothelial bladder cancers are in majority high-grade and seem to grow rapidly with the potential not only to recur, but also to progress to muscle invasion. Therefore, management discussions for patients with a high-grade T1 urothelial bladder cancer are critical. In this review, we aim to give an overview of the controversies encountered in the management of these tumors. Relevant information on T1 urothelial cell bladder cancer was identified through a literature search of published studies and review articles. Establishing an accurate diagnosis is of utmost importance in T1 bladder cancer; particularly understaging can adversely impact the survival of the patient. Therefore, a standard re-TUR is highly recommended in all T1 bladder cancer patients. On the other hand overtreatment affects the quality of life and can lead to unnecessary morbidity. The available treatment options range widely: they include transurethral resection alone with or without re-resection, adding intravesical therapy, radical cystectomy, and bladder sparing techniques using radiotherapy or combined chemoradiation. The choice and timing of the decision whether to pursue with conservative management (TUR and BCG) or to proceed with cystectomy (selected cases with adverse prognostic factors) should be continuously reconsidered on an individual patient basis. This is why the decision making is so difficult, and although we have come along a way in understanding the biological behavior of these tumors, both the choice and timing of treatment remain controversial. After ensuring that accurate staging has been done, the therapeutic options for T1 bladder tumors vary widely (from bladder sparing approaches to cystectomy) and a choice should be made based on individual patient basis.


Assuntos
Carcinoma de Células de Transição/terapia , Neoplasias da Bexiga Urinária/terapia , Adjuvantes Imunológicos/administração & dosagem , Administração Intravesical , Vacina BCG/administração & dosagem , Carcinoma de Células de Transição/tratamento farmacológico , Carcinoma de Células de Transição/patologia , Carcinoma de Células de Transição/radioterapia , Carcinoma de Células de Transição/cirurgia , Quimioterapia Adjuvante , Cistectomia/métodos , Progressão da Doença , Humanos , Gradação de Tumores , Invasividade Neoplásica , Estadiamento de Neoplasias , Radioterapia Adjuvante , Fatores de Risco , Resultado do Tratamento , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/patologia , Neoplasias da Bexiga Urinária/radioterapia , Neoplasias da Bexiga Urinária/cirurgia , Urotélio/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...